Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in Moderately to Severely Active Crohn's Disease
NCT06430801Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 47
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in Crohn's disease (11 arms), sponsored by Merck & Co. Primary endpoints: Clinical Remission per Crohn's Disease Activity Index at 52 weeks, Clinical Remission per Stool Frequency and Abdominal Pain Score at 52 weeks and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06430801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430801.